Literature DB >> 7532321

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

R A Spence1, W M Kati, K S Anderson, K A Johnson.   

Abstract

The mechanism of inhibition of HIV-1 reverse transcriptase by three nonnucleoside inhibitors is described. Nevirapine, O-TIBO, and CI-TIBO each bind to a hydrophobic pocket in the enzyme-DNA complex close to the active site catalytic residues. Pre-steady-state kinetic analysis was used to establish the mechanism of inhibition by these noncompetitive inhibitors. Analysis of the pre-steady-state burst of DNA polymerization indicated that inhibitors blocked the chemical reaction, but did not interfere with nucleotide binding or the nucleotide-induced conformational change. Rather, in the presence of saturating concentrations of the inhibitors, the nucleoside triphosphate bound tightly (Kd, 100 nM), but nonproductively. The data suggest that an inhibitor combining the functionalities of a nonnucleoside inhibitor and a nucleotide analog could bind very tightly and specifically to reverse transcriptase and could be effective in the treatment of AIDS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532321     DOI: 10.1126/science.7532321

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  137 in total

1.  Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.

Authors:  S Hannongbua; P Pungpo; J Limtrakul; P Wolschann
Journal:  J Comput Aided Mol Des       Date:  1999-11       Impact factor: 3.686

2.  Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; H E Aronson; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Molecular matchmaking: NNRTIs can enhance the dimerization of HIV type 1 reverse transcriptase.

Authors:  S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  Kinetics and mechanism of hydrolysis of efavirenz.

Authors:  Michael B Maurin; Susan M Rowe; Karl Blom; Michael E Pierce
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

5.  Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Authors:  J Ren; L E Bird; P P Chamberlain; G B Stewart-Jones; D I Stuart; D K Stammers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-17       Impact factor: 11.205

6.  Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antiviral Res       Date:  2012-06-01       Impact factor: 5.970

Review 7.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

8.  Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

Authors:  Swastika Ganguly; Sankaran Murugesan; Naru Prasanthi; Onur Alptürk; Brian Herman; Nicolas Sluis-Cremer
Journal:  Lett Drug Des Discov       Date:  2010-06-01       Impact factor: 1.150

Review 9.  Allosteric inhibitor development targeting HIV-1 integrase.

Authors:  Laith Q Al-Mawsawi; Nouri Neamati
Journal:  ChemMedChem       Date:  2011-01-12       Impact factor: 3.466

10.  Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.

Authors:  Dongyuan Piao; Aravind Basavapathruni; Pinar Iyidogan; Guangxiu Dai; Wolfgang Hinz; Adrian S Ray; Eisuke Murakami; Joy Y Feng; Fei You; Ginger E Dutschman; David J Austin; Kathlyn A Parker; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2012-12-20       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.